Clinical and microbiologic characteristics of clostridium difficile infection caused by binary toxin producing strain in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jieun | - |
dc.contributor.author | Seo, Mi-ran | - |
dc.contributor.author | Kang, Jung Oak | - |
dc.contributor.author | Choi, Tae Yeal | - |
dc.contributor.author | Pai, Hyunjoo | - |
dc.date.accessioned | 2022-07-16T09:35:40Z | - |
dc.date.available | 2022-07-16T09:35:40Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2013-06 | - |
dc.identifier.issn | 2093-2340 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/162607 | - |
dc.description.abstract | Background: Binary toxin-producing Clostridium difficile infections (CDI) are known to be more severe and to cause higher case fatality rates than those by binary toxin-negative isolates. There has been few data of binary toxin-producing CDI in Korea. Objective of the study is to characterize clinical and microbiological trait of CDI cause by binary-toxin producing isolates in Korea. Materials and Methods: From September 2008 through January 2010, clinical characteristics, medication history and treatment outcome of all the CDI patients were collected prospectively. Toxin characterization, PCR ribotyping and antibiotic susceptibility were performed with the stool isolates of C. difficile . Results: During the period, CDI caused by 11binary toxin-producing isolates and 105 toxin A & toxin B-positive binary toxin-negative isolates were identified. Comparing the disease severity and clinical findings between two groups, leukocytosis and mucoid stool were more frequently observed in patients with binary toxin-positive isolates (OR: 5.2, 95% CI: 1.1 to 25.4, P = 0.043; OR: 7.6, 95% CI: 1.6 to 35.6, P = 0.010, respectively), but clinical outcome of 2 groups did not show any difference. For the risk factors for acquisition of binary toxin-positive isolates, previous use of glycopeptides was the significant risk factor (OR: 6.2, 95% CI: 1.4 to 28.6, P = 0.019), but use of probiotics worked as an inhibitory factor (OR: 0.1, 95% CI: 0.0 to 0.8; P = 0.026). PCR ribotypes of binary toxinproducing C. difficile showed variable patterns: ribotype 130, 4 isolates; 027, 3 isolates; 267 and 122, 1 each isolate and unidentified C1, 2 isolates. All 11 binary toxin-positive isolates were highly susceptible to clindamycin, moxifloxacin, metronidazole, vancomycin and piperacillin-tazobactam, however, 1 of 11 of the isolates was resistant to rifaximin. Conclusions: Binary toxin-producing C. difficile infection was not common in Korea and those isolates showed diverse PCR ribotypes with high susceptibility to antimicrobial agents. Glycopeptide use was a risk factor for CDI by those isolates. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | The Korean Society of Infectious Diseases and Korean Society for Chemotherapy | - |
dc.title | Clinical and microbiologic characteristics of clostridium difficile infection caused by binary toxin producing strain in Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jieun | - |
dc.contributor.affiliatedAuthor | Pai, Hyunjoo | - |
dc.identifier.doi | 10.3947/ic.2013.45.2.175 | - |
dc.identifier.scopusid | 2-s2.0-84884254755 | - |
dc.identifier.bibliographicCitation | Infection and Chemotherapy, v.45, no.2, pp.175 - 183 | - |
dc.relation.isPartOf | Infection and Chemotherapy | - |
dc.citation.title | Infection and Chemotherapy | - |
dc.citation.volume | 45 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 175 | - |
dc.citation.endPage | 183 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001780397 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | binary toxin | - |
dc.subject.keywordPlus | cephalosporin derivative | - |
dc.subject.keywordPlus | clindamycin | - |
dc.subject.keywordPlus | glycopeptide | - |
dc.subject.keywordPlus | metronidazole | - |
dc.subject.keywordPlus | moxifloxacin | - |
dc.subject.keywordPlus | piperacillin plus tazobactam | - |
dc.subject.keywordPlus | probiotic agent | - |
dc.subject.keywordPlus | rifaximin | - |
dc.subject.keywordPlus | toxin | - |
dc.subject.keywordPlus | unclassified drug | - |
dc.subject.keywordPlus | vancomycin | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | antibiotic sensitivity | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | bacterial strain | - |
dc.subject.keywordPlus | bacterium isolate | - |
dc.subject.keywordPlus | Clostridium difficile | - |
dc.subject.keywordPlus | Clostridium difficile infection | - |
dc.subject.keywordPlus | disease severity | - |
dc.subject.keywordPlus | fatality | - |
dc.subject.keywordPlus | feces | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | leukocytosis | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | polymerase chain reaction | - |
dc.subject.keywordPlus | ribotyping | - |
dc.subject.keywordPlus | risk factor | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordAuthor | Binary toxin | - |
dc.subject.keywordAuthor | Clinical characteristics | - |
dc.subject.keywordAuthor | Clostridium difficile | - |
dc.subject.keywordAuthor | PCR ribotype | - |
dc.subject.keywordAuthor | Susceptibility | - |
dc.identifier.url | https://icjournal.org/DOIx.php?id=10.3947/ic.2013.45.2.175 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.